Jefferies Group restated their buy rating on shares of Supernus Pharmaceuticals Inc. (NASDAQ:SUPN) in a research report sent to investors on Wednesday.

Separately, Zacks Investment Research raised Supernus Pharmaceuticals from a hold rating to a buy rating and set a $26.00 price objective on the stock in a report on Wednesday, October 5th. Three investment analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. The stock presently has a consensus rating of Hold and a consensus price target of $25.25.

Supernus Pharmaceuticals (NASDAQ:SUPN) traded up 4.13% during midday trading on Wednesday, hitting $24.60. The stock had a trading volume of 214,265 shares. Supernus Pharmaceuticals has a 52 week low of $9.51 and a 52 week high of $26.84. The company’s 50-day moving average price is $21.70 and its 200 day moving average price is $20.98. The company has a market capitalization of $1217.90 billion, a PE ratio of 49.20 and a beta of 1.86.

In related news, CFO Gregory S. Patrick sold 2,000 shares of the firm’s stock in a transaction that occurred on Friday, September 16th. The shares were sold at an average price of $25.00, for a total value of $50,000.00. Following the sale, the chief financial officer now owns 3,616 shares in the company, valued at $90,400. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 6.10% of the stock is currently owned by corporate insiders.

A number of large investors have recently modified their holdings of SUPN. Louisiana State Employees Retirement System boosted its stake in shares of Supernus Pharmaceuticals by 0.7% in the second quarter. Louisiana State Employees Retirement System now owns 15,300 shares of the specialty pharmaceutical company’s stock valued at $312,000 after buying an additional 100 shares in the last quarter. Municipal Employees Retirement System of Michigan boosted its position in shares of Supernus Pharmaceuticals by 0.9% in the third quarter. Municipal Employees Retirement System of Michigan now owns 14,550 shares of the specialty pharmaceutical company’s stock valued at $360,000 after buying an additional 130 shares in the last quarter. Picton Mahoney Asset Management boosted its position in shares of Supernus Pharmaceuticals by 1.4% in the third quarter. Picton Mahoney Asset Management now owns 15,000 shares of the specialty pharmaceutical company’s stock valued at $371,000 after buying an additional 200 shares in the last quarter. Suntrust Banks Inc. boosted its position in shares of Supernus Pharmaceuticals by 1.5% in the third quarter. Suntrust Banks Inc. now owns 17,976 shares of the specialty pharmaceutical company’s stock valued at $443,000 after buying an additional 273 shares in the last quarter. Finally, Arizona State Retirement System boosted its position in shares of Supernus Pharmaceuticals by 2.3% in the second quarter. Arizona State Retirement System now owns 18,001 shares of the specialty pharmaceutical company’s stock valued at $367,000 after buying an additional 400 shares in the last quarter. Institutional investors own 97.09% of the company’s stock.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. The Company offers products for the treatment of epilepsy, which include extended-release oxcarbazepine (Oxtellar XR) and extended-release topiramate (Trokendi XR).

5 Day Chart for NASDAQ:SUPN

Receive News & Stock Ratings for Supernus Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.